Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Oncology drug development services: an interview with Dr. Jean-Pierre Wery, President of Crown Bioscience, Inc.

Crown serves pharmaceutical companies and biotech companies. We have two areas of focus: oncology and metabolic diseases. In the oncology space we focus on pre-clinical services. Essentially, we have all the tools to help our customers move from target discovery, target validation, to a clinical candidate.

31 Oct 2013

Cellectricon to demonstrate Cellaxess technology at Neuroscience 2013

Cellectricon, a leading provider of advanced cell-based screening technologies and services, will be presenting new data at Neuroscience 2013, 9-13 November, San Diego (USA).

From Cellectricon 31 Oct 2013

STSI receives $29M grant to support innovative research on genomics, wireless technology and bioinformatics

The National Institutes of Health has renewed its prestigious Clinical and Translational Science Award (CTSA) with the Scripps Translational Science Institute (STSI) in the amount of $29 million over the next five years to support innovative research in genomics, wireless technology and bioinformatics toward individualizing medicine.

23 Oct 2013

Sanofi uses QUOSA's literature management tools to automate adverse event monitoring

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced that Sanofi, one of the world's leading pharmaceutical organizations, has implemented QUOSA's literature management tools to automate adverse event monitoring.

22 Oct 2013

Astrazeneca, Evotec Launch Kidney Disease Collaboration

...

21 Oct 2013

Thomson Reuters adds Cortellis Clinical Trials Intelligence for drug discovery and development

The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced the addition of Clinical Trials Intelligence to the Thomson Reuters CortellisTM suite, the industry's most comprehensive information solution for drug discovery and development.

19 Oct 2013

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

...

18 Oct 2013

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

...

17 Oct 2013

Pieris, Zydus Cadila partner to develop and commercialize Anticalin-based protein therapeutics

Zydus Cadila, an innovative global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare products, and Pieris AG, a next generation therapeutic protein R&D company, have entered into an alliance for development and commercialization of multiple novel Anticalin-based protein therapeutics, both companies announced today.

16 Oct 2013

New method may pave way to effective, targeted cancer treatments

Researchers from the University of Minnesota, Mayo Clinic, and University of Toronto have successfully shown that a new method for targeting mutated cells could create a major breakthrough in a personalized medicine approach to treat cancer.

16 Oct 2013

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Crown Bioscience, Inc., a leading global drug discovery and development service company, today announces that it has entered into a collaboration with Xstrahl Ltd, a leading designer and manufacturer of X-Ray solutions for radiation biology research.

From Xstrahl 15 Oct 2013

Researchers discover new approach to tackle global threat of antibiotic drug resistance

Researchers at McMaster University are addressing the crisis in drug resistance with a novel approach to find new antibiotics.

13 Oct 2013

Heptares' StaR platform offers breakthrough solution to challenge associated with antibodies therapeutics

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, achieved the first research milestone in its antibody therapeutics alliance with MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX), announced in February 2013.

10 Oct 2013

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it is advancing its Development Candidate for ALN-AS1, an RNAi therapeutic targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of hepatic porphyrias including acute intermittent porphyria (AIP).

9 Oct 2013

NAC amino acid may offer new treatment options for psychiatric disorders

Improved understanding of the roles of inflammation and oxidative stress in psychiatric disorders has generated new leads in the search for novel therapies. One such investigative compound currently in clinical trials is an amino acid, N-Acetyl Cysteine (NAC), which appears to reduce the core symptoms of bipolar disorder, schizophrenia, depression, autism and cravings in addictions including cocaine, cannabis abuse and cigarette smoking.

8 Oct 2013

Experimental Therapeutics, Debiopharm join to develop oral small molecules targeting new class of epigenetic modulators

The Agency for Science, Technology and Research (A*STAR)'s Experimental Therapeutics Centre (ETC), a center of excellence to advance and accelerate drug discovery in Singapore, and Debiopharm Group™ (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology as well as companion diagnostics, today announced the signature of an exclusive research collaboration to develop oral small molecules targeting new class of epigenetic modulators.

7 Oct 2013

Researchers create catalyst that alters chemical profiles of numerous types of small molecules

Researchers report that they have created a man-made catalyst that is an "enzyme mimic." Unlike most enzymes, which act on a single target, the new catalyst can alter the chemical profiles of numerous types of small molecules.

7 Oct 2013

'Personalised medicine': Topic of free public lecture at the University of Greenwich

'Personalised medicine' is the topic of a free public lecture at the University of Greenwich. Personalised medicine, or precision medicine, as it is sometimes known, is a key goal for 21st century healthcare. Currently, many medicines are either ineffective or unsafe in certain patient populations, whereas the aim for personalised medicine is to target the right treatment to the right patient group.

5 Oct 2013

BioTek’s cell imaging multi-mode reader wins New Product Innovation Award

BioTek’s Cytation™3 Cell Imaging Multi-Mode Reader was recently honored with the first annual New Product Innovation Award, given by MipTec organizers at the 2013 MipTec Conference & Exhibition in Basel, Switzerland. Cytation3 was one of three winning products announced at the exhibition on September 25, 2013.

4 Oct 2013

Regado Axes 15% Of Staff, Focuses On Phase III Trial

...

27 Sep 2013

Drug Discovery News and Research

Further Reading

Oncology drug development services: an interview with Dr. Jean-Pierre Wery, President of Crown Bioscience, Inc.

Cellectricon to demonstrate Cellaxess technology at Neuroscience 2013

STSI receives $29M grant to support innovative research on genomics, wireless technology and bioinformatics

Sanofi uses QUOSA's literature management tools to automate adverse event monitoring

Astrazeneca, Evotec Launch Kidney Disease Collaboration

Thomson Reuters adds Cortellis Clinical Trials Intelligence for drug discovery and development

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

Pieris, Zydus Cadila partner to develop and commercialize Anticalin-based protein therapeutics

New method may pave way to effective, targeted cancer treatments

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Researchers discover new approach to tackle global threat of antibiotic drug resistance

Heptares' StaR platform offers breakthrough solution to challenge associated with antibodies therapeutics

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

NAC amino acid may offer new treatment options for psychiatric disorders

Experimental Therapeutics, Debiopharm join to develop oral small molecules targeting new class of epigenetic modulators

Researchers create catalyst that alters chemical profiles of numerous types of small molecules

'Personalised medicine': Topic of free public lecture at the University of Greenwich

BioTek’s cell imaging multi-mode reader wins New Product Innovation Award

Regado Axes 15% Of Staff, Focuses On Phase III Trial

Event guide: World ADC Asia eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo